{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T23:40:20Z","timestamp":1785541220699,"version":"3.56.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,12,9]],"date-time":"2015-12-09T00:00:00Z","timestamp":1449619200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["No. DEC-2013\/11\/N\/NZ7\/00426"],"award-info":[{"award-number":["No. DEC-2013\/11\/N\/NZ7\/00426"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009045","name":"Jagiellonian University Medical College","doi-asserted-by":"crossref","award":["K\/ZDS\/005545"],"award-info":[{"award-number":["K\/ZDS\/005545"]}],"id":[{"id":"10.13039\/100009045","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s00210-015-1194-2","type":"journal-article","created":{"date-parts":[[2015,12,10]],"date-time":"2015-12-10T02:19:03Z","timestamp":1449713943000},"page":"339-348","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Evaluation of anticonvulsant and antinociceptive properties of new N-Mannich bases derived from pyrrolidine-2,5-dione and 3-methylpyrrolidine-2,5-dione"],"prefix":"10.1007","volume":"389","author":[{"given":"Anna","family":"Rapacz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Rybka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Obniska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinga","family":"Sa\u0142at","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Powro\u017anik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El\u017cbieta","family":"P\u0119kala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Filipek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,9]]},"reference":[{"key":"1194_CR1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejphar.2006.04.009","volume":"539","author":"B Beyreuther","year":"2006","unstructured":"Beyreuther B, Callizot N, St\u00f6hr T (2006) Antinociceptive efficacy of lacosamide in a rat model for painful diabetic neuropathy. Eur J Pharmacol 539:64\u201370","journal-title":"Eur J Pharmacol"},{"key":"1194_CR2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1527-3458.2007.00001.x","volume":"13","author":"BK Beyreuther","year":"2007","unstructured":"Beyreuther BK, Freitag J, Heers C, et al. (2007) Lacosamide: a review of preclinical properties. CNS Drug Rev 13:21\u201342","journal-title":"CNS Drug Rev"},{"key":"1194_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2008.09.005","volume":"83","author":"M Bialer","year":"2009","unstructured":"Bialer M, Johannessen SI, Levy RH, et al. (2009) Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res 83:1\u201343. doi: 10.1016\/j.eplepsyres.2008.09.005","journal-title":"Epilepsy Res"},{"key":"1194_CR4","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.yebeh.2011.05.025","volume":"21","author":"MJ Brodie","year":"2011","unstructured":"Brodie MJ, Covanis A, Gil-Nagel A, et al. (2011) Antiepileptic drug therapy: does mechanism of action matter? Epilepsy Behav 21:331\u2013341. doi: 10.1016\/j.yebeh.2011.05.025","journal-title":"Epilepsy Behav"},{"key":"1194_CR5","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1128\/AEM.66.2.599-605.2000","volume":"66","author":"A Czy\u017c","year":"2000","unstructured":"Czy\u017c A, Jasiecki J, Bogdan A, et al. (2000) Genetically modified Vibrio harveyi strains as potential bioindicators of mutagenic pollution of marine environments. Appl Environ Microbiol 66:599\u2013605","journal-title":"Appl Environ Microbiol"},{"key":"1194_CR6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1383-5718(02)00112-2","volume":"519","author":"A Czy\u017c","year":"2002","unstructured":"Czy\u017c A, Szpilewska H, Dutkiewicz R, et al. (2002) Comparison of the Ames test and a newly developed assay for detection of mutagenic pollution of marine environments. Mutat Res 519:67\u201374","journal-title":"Mutat Res"},{"key":"1194_CR7","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/ptr.3059","volume":"24","author":"M Gulluce","year":"2010","unstructured":"Gulluce M, Agar G, Baris O, et al. (2010) Mutagenic and antimutagenic effects of hexane extract of some Astragalus species grown in the eastern Anatolia region of Turkey. Phytother Res 24:1014\u20131018. doi: 10.1002\/ptr.3059","journal-title":"Phytother Res"},{"key":"1194_CR8","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1016\/j.bmc.2015.03.038","volume":"23","author":"K Kami\u0144ski","year":"2015","unstructured":"Kami\u0144ski K, Rapacz A, \u0141uszczki JJ, et al. (2015a) Design, synthesis and biological evaluation of new hybrid anticonvulsants derived from N-benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide and 2-(2,5-dioxopyrrolidin-1-yl)butanamide derivatives. Bioorg Med Chem 23:2548\u20132561. doi: 10.1016\/j.bmc.2015.03.038","journal-title":"Bioorg Med Chem"},{"key":"1194_CR9","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1021\/acs.jmedchem.5b00578","volume":"58","author":"K Kami\u0144ski","year":"2015","unstructured":"Kami\u0144ski K, Zagaja M, \u0141uszczki JJ, et al. (2015b) Design, synthesis and anticonvulsant activity of new hybrid compounds derived from 2-(2,5-dioxopyrrolidin-1-yl)propanamides and 2-(2,5-dioxopyrrolidin-1-yl)butanamides. J Med Chem 58:5274\u20135286. doi: 10.1021\/acs.jmedchem.5b00578","journal-title":"J Med Chem"},{"key":"1194_CR10","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/ane.12174","volume":"129","author":"C Kellinghaus","year":"2014","unstructured":"Kellinghaus C, Berning S, Immisch I, et al. (2014) Intravenous lacosamide or phenytoin for treatment of refractory status epilepticus. Acta Neurol Scand 129:294\u2013299. doi: 10.1111\/j.1600-0404.2010.01423.x","journal-title":"Acta Neurol Scand"},{"key":"1194_CR11","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ejmech.2014.06.024","volume":"83","author":"P Kowalczyk","year":"2014","unstructured":"Kowalczyk P, Sa\u0142at K, H\u00f6fner G, et al. (2014) Synthesis, biological evaluation and structure-activity relationship of new GABA uptake inhibitors, derivatives of 4-aminobutanamides. Eur J Med Chem 83:256\u2013273. doi: 10.1016\/j.ejmech.2014.06.024","journal-title":"Eur J Med Chem"},{"key":"1194_CR12","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1124\/jpet.302.3.1168","volume":"302","author":"TM Laughlin","year":"2002","unstructured":"Laughlin TM, Tram KV, Wilcox GL, Birnbaum AK (2002) Comparison of antiepileptic drugs tiagabine, lamotrigine, and gabapentin in mouse models of acute, prolonged, and chronic nociception. J Pharmacol Exp Ther 302:1168\u20131175","journal-title":"J Pharmacol Exp Ther"},{"key":"1194_CR13","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00210-013-0938-0","volume":"387","author":"J Listos","year":"2014","unstructured":"Listos J, Talarek S, Orzelska J, et al. (2014) The antinociceptive effect of 4-substituted derivatives of 5-(4-chlorophenyl)-2-(morpholin-4-ylmethyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione in mice. Naunyn Schmiedeberg\u2019s Arch Pharmacol 387:367\u2013375. doi: 10.1007\/s00210-013-0938-0","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"key":"1194_CR14","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0022-3565(25)03549-9","volume":"96","author":"JT Litchfield","year":"1949","unstructured":"Litchfield JT, Wilcoxon F (1949) A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 96:99\u2013113","journal-title":"J Pharmacol Exp Ther"},{"key":"1194_CR15","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0028-3908(02)00400-8","volume":"44","author":"G Liu","year":"2003","unstructured":"Liu G, Yarov-Yarovoy V, Nobbs M, et al. (2003) Differential interactions of lamotrigine and related drugs with transmembrane segment IVS6 of voltage-gated sodium channels. Neuropharmacology 44:413\u2013422","journal-title":"Neuropharmacology"},{"key":"1194_CR16","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1528-1167.2011.03024.x","volume":"52","author":"W L\u00f6scher","year":"2011","unstructured":"L\u00f6scher W, Schmidt D (2011) Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma. Epilepsia 52:657\u2013678. doi: 10.1111\/j.1528-1167.2011.03024.x","journal-title":"Epilepsia"},{"key":"1194_CR17","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0920-1211(91)90075-Q","volume":"8","author":"W L\u00f6scher","year":"1991","unstructured":"L\u00f6scher W, Fassbender CP, Nolting B (1991) The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Res 8:79\u201394","journal-title":"Epilepsy Res"},{"key":"1194_CR18","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s00702-007-0795-4","volume":"114","author":"JJ \u0141uszczki","year":"2007","unstructured":"\u0141uszczki JJ, Jankiewicz K, Jankiewicz M, Czuczwar SJ (2007) Influence of aminophylline on the anticonvulsive action of gabapentin in the mouse maximal electroshock seizure threshold model. J Neural Transm 114:1539\u20131545","journal-title":"J Neural Transm"},{"key":"1194_CR19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1472-8206.2007.00547.x","volume":"22","author":"JJ \u0141uszczki","year":"2008","unstructured":"\u0141uszczki JJ, Swiader MJ, Swiader K, et al. (2008) Anticonvulsant and acute adverse effect profiles of picolinic acid 2-fluoro-benzylamide in various experimental seizure models and chimney test in mice. Fundam Clin Pharmacol 22:69\u201374","journal-title":"Fundam Clin Pharmacol"},{"key":"1194_CR20","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S1474-4422(10)70059-4","volume":"9","author":"M Mantegazza","year":"2010","unstructured":"Mantegazza M, Curia G, Biagini G, et al. (2010) Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. Lancet Neurol 9:413\u2013424. doi: 10.1016\/S1474-4422(10)70059-4","journal-title":"Lancet Neurol"},{"key":"1194_CR21","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2174\/157015906778019527","volume":"4","author":"J Manzanares","year":"2006","unstructured":"Manzanares J, Julian M, Carrascosa A (2006) Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. Curr Neuropharmacol 4:239\u2013257","journal-title":"Curr Neuropharmacol"},{"key":"1194_CR22","first-page":"210","volume":"15","author":"A Muthuraman","year":"2014","unstructured":"Muthuraman A, Singh N, Jaggi AS, Ramesh M (2014) Drug therapy of neuropathic pain: current developments and future perspectives. Curr Drug Targets 15:210\u2013253","journal-title":"Curr Drug Targets"},{"key":"1194_CR23","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejmech.2015.07.017","volume":"102","author":"J Obniska","year":"2015","unstructured":"Obniska J, Rapacz A, Rybka S, et al. (2015) Design, synthesis and biological activity of new amides derived from 3-methyl-3-phenyl-2,5-dioxo-pyrrolidin-1-yl-acetic acid. Eur J Med Chem 102:14\u201325. doi: 10.1016\/j.ejmech.2015.07.017","journal-title":"Eur J Med Chem"},{"key":"1194_CR24","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.mrgentox.2013.07.011","volume":"758","author":"E P\u0119kala","year":"2013","unstructured":"P\u0119kala E, Liana P, Kubowicz P, et al. (2013) Evaluation of mutagenic and antimutagenic properties of new derivatives of pyrrolidine-2,5-dione with anti-epileptic activity, by use of the Vibrio harveyi mutagenicity test. Mutat Res 758:18\u201322. doi: 10.1016\/j.mrgentox.2013.07.011","journal-title":"Mutat Res"},{"key":"1194_CR25","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S1474-4422(07)70215-6","volume":"6","author":"E Perucca","year":"2007","unstructured":"Perucca E, French J, Bialer M (2007) Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol 6:793\u2013804","journal-title":"Lancet Neurol"},{"key":"1194_CR26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.eplepsyres.2005.09.012","volume":"68","author":"MA Rogawski","year":"2006","unstructured":"Rogawski MA (2006) Molecular targets versus models for new antiepileptic drug discovery. Epilepsy Res 68:22\u201328","journal-title":"Epilepsy Res"},{"key":"1194_CR27","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrn1430","volume":"5","author":"MA Rogawski","year":"2004","unstructured":"Rogawski MA, L\u00f6scher W (2004) The neurobiology of antiepileptic drugs. Nat Rev Neurosci 5:553\u2013564","journal-title":"Nat Rev Neurosci"},{"key":"1194_CR28","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/S1474-4422(11)70187-9","volume":"10","author":"AO Rossetti","year":"2011","unstructured":"Rossetti AO, Lowenstein DH (2011) Management of refractory status epilepticus in adults: still more questions than answers. Lancet Neurol 10:922\u2013930. doi: 10.1016\/S1474-4422(11)70187-9","journal-title":"Lancet Neurol"},{"key":"1194_CR29","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/ardp.201400152","volume":"347","author":"S Rybka","year":"2014","unstructured":"Rybka S, Obniska J, Rapacz A, et al. (2014) Synthesis, physicochemical, and anticonvulsant properties of new N-Mannich bases derived from pyrrolidine-2,5-dione and its 3-methyl analog. Arch Pharm (Weinheim) 347:768\u2013776. doi: 10.1002\/ardp.201400152","journal-title":"Arch Pharm (Weinheim)"},{"key":"1194_CR30","doi-asserted-by":"crossref","unstructured":"Rybka S, Obniska J, Rapacz A, et al. (2015) Synthesis and anticonvulsant activity of new N-mannich bases derived from benzhydryl- and isopropyl-pyrrolidine-2,5-dione. J Enzyme Inhib Med Chem Accessed 25 September 2015","DOI":"10.3109\/14756366.2015.1088842"},{"key":"1194_CR31","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.pbb.2011.12.014","volume":"101","author":"K Sa\u0142at","year":"2012","unstructured":"Sa\u0142at K, Moniczewski A, Salat R, et al. (2012) Analgesic, anticonvulsant and antioxidant activities of 3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-dihydrofuran-2-one dihydrochloride in mice. Pharmacol Biochem Behav 101:138\u2013147. doi: 10.1016\/j.pbb.2011.12.014","journal-title":"Pharmacol Biochem Behav"},{"key":"1194_CR32","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.pbb.2014.03.025","volume":"122","author":"K Sa\u0142at","year":"2014","unstructured":"Sa\u0142at K, Cios A, Wyska E, et al. (2014) Antiallodynic and antihyperalgesic activity of 3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-dihydrofuran-2-one compared to pregabalin in chemotherapy-induced neuropathic pain in mice. Pharmacol Biochem Behav 122:173\u2013181. doi: 10.1016\/j.pbb.2014.03.025","journal-title":"Pharmacol Biochem Behav"},{"key":"1194_CR33","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S1474-4422(14)70076-6","volume":"13","author":"M Simonato","year":"2014","unstructured":"Simonato M, Brooks-Kayal AR, Engel Jr J, et al. (2014) The challenge and promise of anti-epileptic therapy development in animal models. Lancet Neurol 13:949\u2013960. doi: 10.1016\/S1474-4422(14)70076-6","journal-title":"Lancet Neurol"},{"key":"1194_CR34","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1472-765X.2009.02781.x","volume":"50","author":"K S\u0142oczy\u0144ska","year":"2010","unstructured":"S\u0142oczy\u0144ska K, P\u0119kala E, Wajda A, et al. (2010) Evaluation of mutagenic and antimutagenic properties of some bioactive xanthone derivatives using Vibrio harveyi test. Lett Appl Microbiol 50:252\u2013257. doi: 10.1111\/j.1472-765X.2009.02781.x","journal-title":"Lett Appl Microbiol"},{"key":"1194_CR35","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ejpain.2005.04.002","volume":"10","author":"T St\u00f6hr","year":"2006","unstructured":"St\u00f6hr T, Krause E, Selve N (2006) Lacosamide displays potent antinociceptive effects in animal models for inflammatory pain. Eur J Pain 10:241\u2013249","journal-title":"Eur J Pain"},{"key":"1194_CR36","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.eplepsyres.2007.03.004","volume":"74","author":"T St\u00f6hr","year":"2007","unstructured":"St\u00f6hr T, Kupferberg HJ, Stables JP, et al. (2007) Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy Res 74:147\u2013154","journal-title":"Epilepsy Res"},{"key":"1194_CR37","first-page":"63","volume":"52","author":"WA Turski","year":"2000","unstructured":"Turski WA (2000) Pilocarpine-induced seizures in rodents-17\u00a0years on. Pol J Pharmacol 52:63\u201365","journal-title":"Pol J Pharmacol"},{"key":"1194_CR38","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/0006-8993(87)90014-X","volume":"414","author":"WA Turski","year":"1987","unstructured":"Turski WA, Herrling PL, Do KQ (1987) Effects of L-cysteine-sulphinate and L-aspartate, mixed excitatory amino acid agonists, on the membrane potential of cat caudate neurons. Brain Res 414:330\u2013338","journal-title":"Brain Res"},{"key":"1194_CR39","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00210-013-0853-4","volume":"386","author":"JC Ximenes","year":"2013","unstructured":"Ximenes JC, de Oliveira GD, Siqueira RM, et al. (2013) Valproic acid: an anticonvulsant drug with potent antinociceptive and anti-inflammatory properties. Naunyn Schmiedeberg\u2019s Arch Pharmacol 386:575\u2013587. doi: 10.1007\/s00210-013-0853-4","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-015-1194-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00210-015-1194-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-015-1194-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T18:42:44Z","timestamp":1748716964000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00210-015-1194-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,9]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["1194"],"URL":"https:\/\/doi.org\/10.1007\/s00210-015-1194-2","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,9]]}}}